Market Place
Sourcing Support
Nona Biosciences and Kodiak Partner on Antibody Therapies
09 Dec 2024 //
PR NEWSWIRE
Kodiak Sciences Announces Q3 2024 Financial Results & Highlights
14 Nov 2024 //
PR NEWSWIRE
Kodiak Sciences to Participate in Upcoming Investor Conferences
11 Nov 2024 //
PR NEWSWIRE
Kodiak Sciences to Present at Innovate Retina 2024
14 Oct 2024 //
PR NEWSWIRE
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
17 Sep 2024 //
PR NEWSWIRE
Kodiak Sciences Reports Q2 2024 Results And Recent Business Highlights
14 Aug 2024 //
PR NEWSWIRE
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
29 May 2024 //
PR NEWSWIRE
Kodiak Sciences Q1 2024 Highlights And Financials
15 May 2024 //
PR NEWSWIRE
Kodiak Initiates GLOW2 Phase 3 Trial Of Tarcocimab In Diabetic Retinopathy
13 May 2024 //
PR NEWSWIRE
Kodiak Announces Recent Business Highlights and Q4 and FY23 Financial Results
28 Mar 2024 //
PR NEWSWIRE
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results
26 Mar 2024 //
PR NEWSWIRE
Kodiak Announces Presentation of First Time Results of KSI-501ABC Phase 1 Study
30 Jan 2024 //
PR NEWSWIRE
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
PR NEWSWIRE
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
PR NEWSWIRE
Kodiak reboots tarcocimab tedromer development program
06 Nov 2023 //
PR NEWSWIRE
Kodiak resurrects eye drug after ph. 3 data renew approval plans
06 Nov 2023 //
FIERCE BIOTECH
Kodiak Announces First Time Presentation Of Data From Tarcocimab Tedromer
01 Nov 2023 //
PR NEWSWIRE
Kodiak Sciences Announces Upcoming Presentations at Retina Society
11 Oct 2023 //
PR NEWSWIRE
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Conference
08 Sep 2023 //
PR NEWSWIRE
Kodiak`s CMO hands in notice a month after pair of phase 3 fails
18 Aug 2023 //
FIERCE BIOTECH
Kodiak Sciences Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
PR NEWSWIRE
Kodiak Sciences scraps development of eye drug, shares slump
25 Jul 2023 //
REUTERS
Kodiak Sciences to Present at Upcoming Investor Conferences
30 May 2023 //
PR NEWSWIRE
Kodiak Sciences Announces 1Q 2023 FYR Results and Recent Business Highlights
15 May 2023 //
PR NEWSWIRE
Kodiak Sciences Announces Presentations at ARVO 2023 Annual Meeting
21 Apr 2023 //
PR NEWSWIRE
Kodiak Expands Development Pipeline in Phase 1 Clinical Study of KSI-501
03 Apr 2023 //
PR NEWSWIRE
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
PR NEWSWIRE
Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
16 Nov 2022 //
PRNEWSWIRE
Kodiak Sciences Announces Third Quarter 2022 FYR and Recent Business Highlights
09 Nov 2022 //
PRNEWSWIRE
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
07 Sep 2022 //
PRNEWSWIRE
Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer
18 Aug 2022 //
PRNEWSWIRE
Kodiak Sciences Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
PRNEWSWIRE
Kodiak Reports Positive Topline Results from BEACON PIII Study of KSI-301
08 Aug 2022 //
PRNEWSWIRE
Kodiak Sciences Completes Enrollment in PIII Trial of Tarcocimab Tedromer
05 Aug 2022 //
PRESS RELEASE
Why Kodiak Sciences Stock Is Sharply Lower Today
02 Aug 2022 //
FOOL
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?
09 Jun 2022 //
YAHOO FINANCE
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
27 May 2022 //
PRNEWSWIRE
Kodiak Sciences Announces First Quarter 2022 Financial Results
10 May 2022 //
PRNEWSWIRE
Kodiak Sciences to Present KSI-301 Phase 2b/3 Study Data in wet AMD
29 Apr 2022 //
PRNEWSWIRE
Kodiak Sciences Announces Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
PRNEWSWIRE
Kodiak`s vision loss drug flops in it`s phase 3 studies
24 Feb 2022 //
MEDCITYNEWS
Kodiak Sciences Shows Top-Line Results from initial Phase 2b/3 Study of KSI-301
23 Feb 2022 //
PRESS RELEASE
Enrollment in two Phase 3 Trials of KSI-301 in Diabetic Macular Edema
03 Feb 2022 //
PRESS RELEASE
Kodiak Sciences Completes Enrollment in BEACON Phase 3 Trial of KSI-301
16 Dec 2021 //
PRNEWSWIRE
Kodiak to Present at the Morgan Stanley 19th Global Healthcare Conference
31 Aug 2021 //
PRNEWSWIRE
Kodiak turns down $125M payment from Baker Bros. deal
23 Jul 2021 //
ENDPTS
Kodiak Announces 1-Year Durability, Efficacy and Safety Data from Ongoing
15 Feb 2021 //
PRNEWSWIRE
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Study Data
02 Feb 2021 //
PRNEWSWIRE
Kodiak Sciences Completes of DAZZLE Phase 2b/3 Pivotal Study of KSI-301
16 Nov 2020 //
PRNEWSWIRE
Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data
11 Nov 2020 //
PRNEWSWIRE
Kodiak, Lonza Sign Long-Term Manufacturing Contract
28 Jul 2020 //
CONTRACTPHARMA
Kodiak Sciences to Host R&D Webcast to ReviewPhase 1b Study of KSI-301
16 Jul 2020 //
PRNEWSWIRE
Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data
10 Jul 2020 //
PRNEWSWIRE
Kodiak Sciences Announces New Longer-Term Safety, Efficac KSI-301 in Patients
10 Jul 2020 //
PHARMIWEB
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data
07 Jul 2020 //
PRNEWSWIRE
Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost
24 Jun 2020 //
ENDPTS
Kodiak Sciences Announces Additional Safety Data from Ongoing Ph1b Study KSI-301
09 Feb 2020 //
PR NEWSWIRE
Kodiak Sciences Announces Additional Safety Data from Ongoing Ph1b Study KSI-301
09 Feb 2020 //
PR NEWSWIRE
Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301
05 Feb 2020 //
PR NEWSWIRE
